News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
168,733 Results
Type
Article (6974)
Company Profile (40)
Press Release (161719)
Multimedia
Podcasts (9)
Webinars (3)
Section
Business (48802)
Career Advice (484)
Deals (9572)
Drug Delivery (18)
Drug Development (34185)
Employer Resources (20)
FDA (4419)
Job Trends (3757)
News (93254)
Policy (6565)
Tag
2024 Bio NC Digital (1)
2024 Biotech Bay Standard (4)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (2)
2024 Pharm Country Standard (2)
2025 Lone Star Bio Digital (1)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Bio NC Standard (1)
2026 Genetown Elite (1)
2026 Genetown Standard (1)
2026 Pharm Country Standard (1)
Academia (505)
Academic (1)
Accelerated approval (3)
Adcomms (8)
Allergies (32)
Alliances (8251)
ALS (37)
Alzheimer's disease (548)
Antibody-drug conjugate (ADC) (43)
Approvals (4478)
Artificial intelligence (58)
Autoimmune disease (5)
Automation (4)
Bankruptcy (65)
Best Places to Work (3503)
BIOSECURE Act (6)
Biosimilars (31)
Biotechnology (32)
Bladder cancer (27)
Brain cancer (6)
Breast cancer (140)
Cancer (1002)
Cardiovascular disease (77)
Career advice (379)
Career pathing (6)
CAR-T (50)
Cell therapy (150)
Cervical cancer (9)
Clinical research (29317)
Collaboration (228)
Compensation (67)
Complete response letters (3)
COVID-19 (757)
CRISPR (15)
C-suite (37)
Cystic fibrosis (39)
Data (1188)
Depression (15)
Diabetes (133)
Diagnostics (1612)
Digital health (3)
Diversity, equity & inclusion (4)
Drug discovery (39)
Drug pricing (11)
Drug shortages (2)
Duchenne muscular dystrophy (32)
Earnings (32240)
Editorial (13)
Employer branding (1)
Employer resources (20)
Events (28317)
Executive appointments (145)
FDA (4972)
Featured Employer (15)
Frontotemporal dementia (1)
Funding (249)
Gene editing (37)
Generative AI (4)
Gene therapy (117)
GLP-1 (312)
Government (871)
Grass and pollen (2)
Guidances (33)
Healthcare (4784)
Huntington's disease (6)
IgA nephropathy (19)
Immunology and inflammation (43)
Indications (17)
Infectious disease (808)
Inflammatory bowel disease (56)
Inflation Reduction Act (2)
Influenza (29)
Intellectual property (38)
Interviews (89)
IPO (5902)
IRA (7)
Job creations (496)
Job search strategy (325)
Kidney cancer (6)
Labor market (9)
Layoffs (72)
Leadership (4)
Legal (877)
Liver cancer (31)
Lung cancer (177)
Lymphoma (78)
Management (6)
Manufacturing (62)
MASH (31)
Medical device (2857)
Medtech (2857)
Mergers & acquisitions (3901)
Metabolic disorders (287)
Multiple sclerosis (31)
NASH (6)
Neurodegenerative disease (33)
Neuropsychiatric disorders (10)
Neuroscience (760)
NextGen: Class of 2025 (1262)
Non-profit (643)
Northern California (1084)
Now hiring (2)
Obesity (136)
Opinion (45)
Ovarian cancer (32)
Pain (40)
Pancreatic cancer (36)
Parkinson's disease (76)
Partnered (3)
Patents (58)
Patient recruitment (43)
Peanut (17)
People (8015)
Pharmaceutical (9)
Pharmacy benefit managers (1)
Phase I (8529)
Phase II (14416)
Phase III (9443)
Pipeline (715)
Policy (30)
Postmarket research (888)
Preclinical (2711)
Press Release (7)
Prostate cancer (43)
Psychedelics (8)
Radiopharmaceuticals (84)
Rare diseases (147)
Real estate (573)
Recruiting (10)
Regulatory (5581)
Reports (19)
Research institute (501)
Resumes & cover letters (96)
Rett syndrome (2)
RNA editing (2)
RSV (18)
Schizophrenia (35)
Series A (60)
Series B (26)
Service/supplier (2)
Sickle cell disease (26)
Southern California (923)
Special edition (6)
Spinal muscular atrophy (43)
Sponsored (9)
Startups (698)
State (1)
Stomach cancer (5)
Supply chain (10)
Tariffs (4)
The Weekly (9)
United States (8317)
Vaccines (190)
Venture capitalists (10)
Weight loss (68)
Women's health (5)
Worklife (4)
Date
Last 7 days (162)
Last 30 days (896)
Last 365 days (13226)
2025 (3759)
2024 (13517)
2023 (14784)
2022 (17492)
2021 (17689)
2020 (15676)
2019 (11147)
2018 (8294)
2017 (8638)
2016 (7267)
2015 (8838)
2014 (5985)
2013 (4071)
2012 (4255)
2011 (4684)
2010 (4184)
Location
Africa (163)
Alabama (14)
Alaska (1)
Arizona (28)
Arkansas (3)
Asia (10571)
Australia (1770)
California (2394)
Canada (776)
China (199)
Colorado (95)
Connecticut (123)
Delaware (68)
Europe (25249)
Florida (308)
Georgia (86)
Idaho (11)
Illinois (140)
India (6)
Indiana (100)
Japan (75)
Kansas (35)
Kentucky (8)
Maine (23)
Maryland (285)
Massachusetts (1679)
Michigan (60)
Minnesota (107)
Missouri (23)
Montana (4)
Nebraska (2)
Nevada (21)
New Hampshire (10)
New Jersey (728)
New Mexico (3)
New York (681)
North Carolina (237)
North Dakota (2)
Northern California (1084)
Ohio (45)
Oklahoma (1)
Oregon (6)
Pennsylvania (549)
Puerto Rico (3)
Rhode Island (4)
South America (283)
South Carolina (1)
Southern California (923)
Tennessee (22)
Texas (338)
Utah (47)
Virginia (47)
Washington D.C. (22)
Washington State (193)
Wisconsin (10)
168,733 Results for "a2 biotherapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Antibody-drug conjugate (ADC)
Roche Ups ADC Bet With $1B in Biobucks for Oxford BioTherapeutics
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.
March 19, 2025
·
1 min read
·
Tristan Manalac
Press Releases
A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of Its Precision Cell Therapies Using Its Proprietary Tmod™ Technology Platform
January 9, 2025
·
2 min read
Drug Development
A2 Bio Announces First Patient Dosed in EVEREST-2 Phase 1 Clinical Trial of Novel Mesothelin Logic-Gated CAR T
A2 Biotherapeutics, Inc. today announced dosing of the first patient in the Phase 1 clinical trial of A2B694.
May 16, 2024
·
3 min read
Press Releases
Interius BioTherapeutics to Present at Upcoming Scientific Meetings
April 17, 2025
·
2 min read
Press Releases
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial
April 15, 2025
·
5 min read
FDA
A2 Bio Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530 in Colorectal Cancer
A2 Biotherapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to A2B530 for the treatment of germline heterozygous HLA-A*02(+) patients with colorectal cancer that expresses carcinoembryonic antigen (CEA) and has lost HLA-A*02 expression.
March 4, 2024
·
2 min read
Press Releases
Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors
April 17, 2025
·
4 min read
Press Releases
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
April 8, 2025
·
7 min read
Press Releases
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
April 1, 2025
·
3 min read
Press Releases
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
March 31, 2025
·
8 min read
1 of 16,874
Next
